Immunogenicity 

Gyrolab® delivers accurate results in a fraction of the time and with fewer manual steps.

Assessment of anti-drug antibodies (ADAs) as well as neutralizing antibodies (NAbs) is a fundamental part of immunogenicity testing. ADA immunoassays for biotherapeutics are extremely complex and require lengthy protocols to maximize drug tolerance, minimize drug interference and establish equilibrium, using methods such as overnight incubations and acid sample pretreatment.

Gyrolab feature/benefits for ADA immunoassays:

  • Reduces hands-on time
    Automated sample pretreatment and assay workflows
  • Shorten overall run times
    Results can be obtained in as little as one hour
  • Saves precious reagents and samples
    5 µL sample is sufficient for duplicates
  • Streamlines workflows from assay development through screening to confirmation:
    Gyrolab ADA protocol and dedicated Gyrolab ADA analysis software

Gyrolab ADA solution provides nanoliter-scale methods for ADA detection using automated acid dissociation or offline incubation. Working at nanoliter-scale reduces processing times and minimizes sample/reagent consumption. Dedicated Gyrolab ADA software, designed for  21 CFR Part 11 compliance, facilitates data analysis for either screening or confirmatory results. Gyrolab systems produce assays exhibiting high drug tolerance coupled with high sensitivity and consistent performance providing high quality data.

ada-sw1.png

 Gyrolab ADA Software

Assessment of neutralizing antibodies (NAb)

NAb detection is an important aspect of immunogenicity assessment, requiring sensitive and reliable methods reflective of the therapeutic mechanism of action (MoA). Two types of Nab assays are mainly used; a non-cell-based competitive ligand binding assay (e.g. Gyrolab) or a cell-based bioassay.

With iLite® Assay Ready Cells, presence of neutralizing antibodies can be assessed in both screening and quantitative format.

Learn More
    Gyrolab Systems
    Gyrolab technology reduces manual labor, assay development time, time to result and material consumption -and it improves workflow efficiency. 
    [Brochure]

    Gyrolab ADA solutions
    Gyrolab ADA solution provides nanoliter-scale methods for ADA detection using automated acid dissociation or offline incubation. Dedicated software facilitates data analysis for either screening or confirmatory results.  
    [Product information sheet]

    Evaluation of Gyrolab™ and Meso-Scale Discovery platforms in the development of a clinical immunogenicity assay
    J Collet, A Moreau et. al. NovImmune SA, Geneva, Switzerland 
    [Poster]

    Sabrina Lory Developing fit-for-purpose immunoassays
    Recorded Seminar: Sabrina Lory, Head of the Bioanalytical Assay Laboratory, NovImmune, presents ‘Developing fit for purpose assays using the Gyrolab platform'. 
    [Seminar]

    Assessing the immunogenicity of biopharmaceuticals
    Recorded Webinar: Immunogenicity of therapeutic biopharmaceuticals can impact both the efficacy and the safety of the product. Assessment of anti-drug antibodies (ADAs) as well as neutralizing antibodies (NAbs) is a fundamental part of immunogenicity testing. Presenters: Cecilia Bill, Gyros Protein Technologies and Frida Pauly, Euro Diagnostica. 
    [Webinar]

    Rapid Reagent Screening and Characterization using Automated Nanoliter-scale Immunoassays
    Recorded Webinar: Gyrolab is a reliable immunoassay platform that streamlines reagent selection and characterization during method development for biotherapeutics. Presenters: Frank Zambito, Research Scientist I, Bioanalytical Sciences, Bristol-Myers Squibb and Shawn Fernando, Senior Principal Researcher, Morphotek, Inc. 
    [Webinar]